Vir Biotechnology (VIR) FCF Margin (2018 - 2026)

Vir Biotechnology has disclosed FCF Margin across 9 years of filings, most recently posting 457848.28% for Q1 2026.

• FCF Margin for Q1 2026 came in at 457848.28%, down 45521816.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 685.92% (up 133764.0% YoY), and the FY2025 annual result was 578.52%, up 3283.0% from the prior year.
• FCF Margin came in at 457848.28% for Q1 2026 at Vir Biotechnology, down from 40.93% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 2312.48% in Q2 2022 to a low of 457848.28% in Q1 2026.
• The 5-year median for FCF Margin is 724.34% (2024), against an average of 33316.42%.
• Across the five-year window, FCF Margin jumped 794723 bps in 2024 and sank 45521816 bps in 2026, its largest moves.
• Vir Biotechnology's FCF Margin stood at 45.64% in 2022, then tumbled by 1529 bps to 652.06% in 2023, then declined by 11 bps to 724.34% in 2024, then jumped by 94 bps to 40.93% in 2025, then plunged by 1118507 bps to 457848.28% in 2026.
• The last three FCF Margin figures came in at 457848.28% (Q1 2026), 40.93% (Q4 2025), and 69952.92% (Q3 2025), per Business Quant data.